NGF May Provide Key to Reversing Effects of Alzheimer's
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




NGF May Provide Key to Reversing Effects of Alzheimer's

WASHINGTON, MD. -- October 2, 1997 -- For the first time, scientists have shown through genetic studies in adult mice that depletion of the protein nerve growth factor (NGF) causes a decline in learning and memory, mimicking a major characteristic of Alzheimer’s disease. An estimated four million Americans are affected by the degenerative ailment.

"We also have found that NGF can bring learning and memory back to normal levels in spite of the loss of about one-third of a population of cells that are important for learning and memory," said Heidi Phillips of Genentech, Inc. in San Francisco. "The finding is intriguing and adds encouragement for therapeutic approaches for Alzheimer's disease based on the principle of increasing the function of remaining brain cells."

Her study is published in the October 1 issue of The Journal of Neuroscience.

"This is an important advance and brings us one step closer to clinical relevance," said Ira Black, an expert on NGF at Robert Wood Johnson Medical School in New Jersey. "For the first time it demonstrates that memory deficits in a genetic model possibly can be treated with prolonged infusion of NGF into the brain."

In the past, researchers suspected NGF was important for the function and survival of a population of cells crucial for learning and memory -- basal forebrain cholinergic neurons.

"These cells undergo degeneration in Alzheimer’s disease and their loss is believed to contribute to the memory loss observed in the disease," Phillips explained. In previous work, scientists found the administration of NGF to injured basal forebrain cholinergic neurons could improve cognitive function in elderly rats.

In the research, Phillips and her colleagues studied mice bred to carry one dysfunctional copy and one normal copy of the NGF gene. (For each inherited characteristic, an organism has two genes, one inherited from each parent). Mice lacking both copies of the gene do not live long enough to study. The mice Phillips studied have learning and memory losses similar to Alzheimer's.

"The mice bearing one dysfunctional NGF gene have reduced levels of NGF in the brain, show a loss of about one-third of their basal forebrain cholinergic neurons and display a mild, but significant impairment of performance in a learning and memory task," Phillips said. "The remaining basal forebrain cholinergic neurons are shrunken in size, indicating that they are not functioning optimally."

These results show that NGF is critical for the development, survival and function of this cell population.

"In the second step of the study, administering NGF not only reverses the cell shrinkage, but also completely reverses the learning and memory deficits in these mice," Phillips explained.

The scientists are optimistic that these findings could lead to further research resulting in ways to successfully treat Alzheimer’s disease and other memory disorders. NGF is now being studied for the treatment of diseases that involve defects in another type of neuron. These neurons, known as sensory neurons, convey pain and temperature information. Currently, NGF is in human clinical trials for the treatment of diabetic peripheral neuropathy and HIV-related neuropathy.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities